CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ARPC2 (ImmuneEditome ID:10109)

1. Gene summary of enriched editing regions for ARPC2

check button Gene summary
Gene informationGene symbol

ARPC2

Gene ID

10109

GeneSynonymsARC34|PNAS-139|PRO2446|p34-Arc
GeneCytomap

2q35

GeneTypeprotein-coding
GeneDescriptionactin-related protein 2/3 complex subunit 2|ARP2/3 protein complex subunit 34|actin related protein 2/3 complex, subunit 2, 34kDa|arp2/3 complex 34 kDa subunit|testis tissue sperm-binding protein Li 53e
GeneModificationdate20230409
UniprotIDO15144;G5E9S7;Q53R19;G5E9J0;H7C3F9;C9JTV5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:218231826-218234095:+ENST00000470146.4ENSG00000163466.14ARPC2ncRNA_exonicA-rich,MSTD,AluY,AluSp,AluSx1,AluJr,AluSzchr2:218231826-218234095:+.alignment
chr2:218235187-218237907:+ENST00000477992.1ENSG00000163466.14ARPC2ncRNA_exonicAluJr,MIRb,AluSx1,AluSp,AluSqchr2:218235187-218237907:+.alignment
chr2:218235187-218237907:+ENST00000484961.1ENSG00000163466.14ARPC2ncRNA_exonicAluJr,MIRb,AluSx1,AluSp,AluSqchr2:218235187-218237907:+.alignment
chr2:218235187-218237907:+ENST00000491780.4ENSG00000163466.14ARPC2ncRNA_exonicAluJr,MIRb,AluSx1,AluSp,AluSqchr2:218235187-218237907:+.alignment
chr2:218246650-218246947:+ENST00000470146.4ENSG00000163466.14ARPC2ncRNA_intronicAluSz,AluJbchr2:218246650-218246947:+.alignment
chr2:218246650-218246947:+ENST00000477992.1ENSG00000163466.14ARPC2ncRNA_intronicAluSz,AluJbchr2:218246650-218246947:+.alignment
chr2:218247978-218248771:+ENST00000470146.4ENSG00000163466.14ARPC2ncRNA_intronicMER104,AluSz6,AluSxchr2:218247978-218248771:+.alignment
chr2:218247978-218248771:+ENST00000477992.1ENSG00000163466.14ARPC2ncRNA_intronicMER104,AluSz6,AluSxchr2:218247978-218248771:+.alignment
chr2:218251240-218252221:+ENST00000470146.4ENSG00000163466.14ARPC2ncRNA_intronicAluJb,AluSx3,AluSpchr2:218251240-218252221:+.alignment
chr2:218251240-218252221:+ENST00000477992.1ENSG00000163466.14ARPC2ncRNA_intronicAluJb,AluSx3,AluSpchr2:218251240-218252221:+.alignment
chr2:218251240-218252221:+ENST00000487321.1ENSG00000163466.14ARPC2ncRNA_intronicAluJb,AluSx3,AluSpchr2:218251240-218252221:+.alignment


Top

2. Tumor-specific enriched editing regions for ARPC2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:218235187-218237907:+LUADEER1.6668e-02image
ENSG00000163466.14,ARPC2LUADEAG1.5123e-02image
chr2:218235187-218237907:+LUSCEER5.9918e-03image
ENSG00000163466.14,ARPC2LUSCEAG6.5011e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr2:218235187-218237907:+ESCAPathEER1.6277e-025.3539e-030.2359image
ENSG00000163466.14,ARPC2ESCAPathEAG1.2786e-024.2629e-030.2410image
ENSG00000163466.14,ARPC2KIRPPathEAG6.1520e-031.2558e-020.2779image
chr2:218235187-218237907:+KIRPPathEER5.9891e-031.2648e-020.2776image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ARPC2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:218235187-218237907:+ESCAEERENSG00000220583,RPL35P20.33837.5722e-032.3911e-070.4007imageNNNANK_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr2:218235187-218237907:+ESCAEERENSG00000197575,RPS17P20.33449.2101e-031.0045e-090.4659imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr2:218235187-218237907:+ESCAEERENSG00000237991,RPL35P10.32491.2348e-021.4429e-080.4358imageNNNANK_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr2:218235187-218237907:+ESCAEERENSG00000232346,SC22CB-1E7.10.29133.0511e-024.6121e-080.4218imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr2:218235187-218237907:+ESCAEERENSG00000220583,RPL35P20.33837.5722e-032.3911e-070.4007imageNNNANK_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr2:218235187-218237907:+ESCAEERENSG00000197575,RPS17P20.33449.2101e-031.0045e-090.4659imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr2:218235187-218237907:+ESCAEERENSG00000237991,RPL35P10.32491.2348e-021.4429e-080.4358imageNNNANK_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr2:218235187-218237907:+ESCAEERENSG00000232346,SC22CB-1E7.10.29133.0511e-024.6121e-080.4218imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr2:218235187-218237907:+ESCAEERENSG00000220583,RPL35P20.33837.5722e-032.3911e-070.4007imageNNNANK_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr2:218235187-218237907:+ESCAEERENSG00000197575,RPS17P20.33449.2101e-031.0045e-090.4659imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
chr2:218235187-218237907:+ESCAEERENSG00000237991,RPL35P10.32491.2348e-021.4429e-080.4358imageNNNANK_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr2:218235187-218237907:+ESCAEERENSG00000232346,SC22CB-1E7.10.29133.0511e-024.6121e-080.4218imageNNNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for ARPC2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:218235187-218237907:+
ESCAEERA3ENSG00000135074.11chr5157481790:157481943:157477303:157477735:157477303:1574810020.28524.5202e-021.9307e-070.4330imageNNADAM19T_cells_follicular_helperGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for ARPC2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:218235187-218237907:+BLCAEERT_cells_CD4_naive7.4008e-03-0.1958image
ENSG00000163466.14,ARPC2BLCAEAGT_cells_CD4_naive6.2287e-03-0.1999image
chr2:218235187-218237907:+BRCAEERNK_cells_activated5.2170e-040.1812image
ENSG00000163466.14,ARPC2BRCAEAGNK_cells_activated5.5472e-040.1799image
chr2:218235187-218237907:+DLBCEERPlasma_cells3.4035e-020.4642image
ENSG00000163466.14,ARPC2DLBCEAGPlasma_cells3.4054e-020.4641image
chr2:218231826-218234095:+ESCAEEREosinophils4.9315e-020.2915image
chr2:218235187-218237907:+ESCAEERT_cells_CD4_memory_resting3.8310e-02-0.1666image
chr2:218251240-218252221:+ESCAEERMast_cells_activated3.2240e-060.8301image
ENSG00000163466.14,ARPC2ESCAEAGT_cells_CD4_memory_resting3.0788e-02-0.1730image
chr2:218235187-218237907:+GBMEERMast_cells_activated6.1434e-040.4513image
ENSG00000163466.14,ARPC2GBMEAGMast_cells_activated5.9804e-040.4522image
chr2:218235187-218237907:+KIRCEERDendritic_cells_activated7.6362e-030.2064image
ENSG00000163466.14,ARPC2KIRCEAGDendritic_cells_activated7.3449e-030.2074image
chr2:218235187-218237907:+KIRPEERT_cells_CD4_memory_activated2.8253e-040.3760image
ENSG00000163466.14,ARPC2KIRPEAGT_cells_CD4_memory_activated2.8307e-040.3759image
chr2:218235187-218237907:+LAMLEERT_cells_regulatory_(Tregs)8.0413e-030.2156image
ENSG00000163466.14,ARPC2LAMLEAGT_cells_regulatory_(Tregs)1.6397e-020.1957image
chr2:218235187-218237907:+LGGEERDendritic_cells_activated4.4123e-020.2104image
ENSG00000163466.14,ARPC2LGGEAGDendritic_cells_activated4.4123e-020.2104image
chr2:218235187-218237907:+LUADEERT_cells_CD4_memory_resting9.8093e-04-0.1953image
ENSG00000163466.14,ARPC2LUADEAGT_cells_CD4_memory_resting1.0494e-03-0.1938image
chr2:218235187-218237907:+LUSCEERT_cells_CD85.6883e-030.1471image
ENSG00000163466.14,ARPC2LUSCEAGT_cells_CD86.0484e-030.1458image
chr2:218235187-218237907:+MESOEERMast_cells_activated3.3559e-020.3767image
ENSG00000163466.14,ARPC2MESOEAGMast_cells_activated3.3559e-020.3767image
chr2:218235187-218237907:+OVEERT_cells_CD4_memory_resting2.8996e-04-0.2642image
ENSG00000163466.14,ARPC2OVEAGT_cells_CD4_memory_resting3.0405e-04-0.2633image
chr2:218235187-218237907:+SARCEERT_cells_gamma_delta1.6355e-020.3729image
ENSG00000163466.14,ARPC2SARCEAGT_cells_gamma_delta1.6355e-020.3729image
chr2:218231826-218234095:+STADEERNK_cells_activated1.2299e-02-0.2978image
chr2:218235187-218237907:+STADEERB_cells_memory3.1086e-03-0.1722image
ENSG00000163466.14,ARPC2STADEAGB_cells_memory2.2642e-03-0.1751image
chr2:218235187-218237907:+TGCTEERMast_cells_resting2.2729e-02-0.2740image
ENSG00000163466.14,ARPC2TGCTEAGMast_cells_resting2.2729e-02-0.2740image
chr2:218235187-218237907:+THCAEERMacrophages_M01.0901e-02-0.2749image
ENSG00000163466.14,ARPC2THCAEAGMacrophages_M01.0901e-02-0.2749image
chr2:218235187-218237907:+THYMEERMast_cells_resting3.9680e-020.3044image
ENSG00000163466.14,ARPC2THYMEAGMast_cells_resting3.9680e-020.3044image
ENSG00000163466.14,ARPC2UCECEAGT_cells_gamma_delta1.3236e-020.5436image


Top

6. Enriched editing regions and immune gene sets for ARPC2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000163466.14,ARPC2BLCAGSVA_HALLMARK_SPERMATOGENESISEAG1.7017e-030.2286image
chr2:218235187-218237907:+BLCAGSVA_HALLMARK_SPERMATOGENESISEER1.7889e-030.2275image
ENSG00000163466.14,ARPC2BRCAGSVA_HALLMARK_PEROXISOMEEAG1.3796e-030.1668image
chr2:218235187-218237907:+BRCAGSVA_HALLMARK_PEROXISOMEEER6.4852e-040.1782image
chr2:218235187-218237907:+CESCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER3.9156e-02-0.2131image
ENSG00000163466.14,ARPC2CESCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG3.8464e-02-0.2139image
ENSG00000163466.14,ARPC2ESCAGSVA_HALLMARK_KRAS_SIGNALING_UPEAG6.2093e-03-0.2182image
chr2:218251240-218252221:+ESCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.2909e-020.4938image
chr2:218235187-218237907:+ESCAGSVA_HALLMARK_KRAS_SIGNALING_UPEER7.1158e-03-0.2154image
chr2:218235187-218237907:+GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.0014e-030.4113image
ENSG00000163466.14,ARPC2GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.1024e-030.4096image
chr2:218235187-218237907:+HNSCGSVA_HALLMARK_ADIPOGENESISEER7.2808e-030.2390image
ENSG00000163466.14,ARPC2HNSCGSVA_HALLMARK_ADIPOGENESISEAG7.6519e-030.2375image
ENSG00000163466.14,ARPC2KIRCGSVA_HALLMARK_APICAL_SURFACEEAG4.8069e-020.1537image
chr2:218235187-218237907:+KIRCGSVA_HALLMARK_APICAL_SURFACEEER4.8425e-020.1534image
chr2:218235187-218237907:+LAMLGSVA_HALLMARK_HEME_METABOLISMEER2.4080e-020.1842image
ENSG00000163466.14,ARPC2LAMLGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.3715e-02-0.1735image
chr2:218235187-218237907:+LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.3590e-02-0.2109image
ENSG00000163466.14,ARPC2LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.3590e-02-0.2109image
chr2:218235187-218237907:+LUADGSVA_HALLMARK_DNA_REPAIREER9.5345e-060.2602image
ENSG00000163466.14,ARPC2LUADGSVA_HALLMARK_DNA_REPAIREAG1.0211e-050.2590image
chr2:218235187-218237907:+LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEER4.4490e-070.2652image
ENSG00000163466.14,ARPC2LUSCGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.5095e-070.2671image
chr2:218235187-218237907:+OVGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.3193e-02-0.1571image
ENSG00000163466.14,ARPC2OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.7187e-020.1629image
chr2:218235187-218237907:+PAADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.7101e-020.2270image
ENSG00000163466.14,ARPC2PAADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.8243e-020.2248image
ENSG00000163466.14,ARPC2PRADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.4099e-02-0.4169image
ENSG00000163466.14,ARPC2READGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG7.2604e-040.5066image
chr2:218235187-218237907:+READGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER7.2604e-040.5066image
chr2:218235187-218237907:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1443e-030.4502image
ENSG00000163466.14,ARPC2SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1443e-030.4502image
chr2:218235187-218237907:+SKCMGSVA_HALLMARK_ADIPOGENESISEER1.5105e-020.2072image
ENSG00000163466.14,ARPC2SKCMGSVA_HALLMARK_ADIPOGENESISEAG1.5105e-020.2072image
chr2:218235187-218237907:+STADGSVA_HALLMARK_DNA_REPAIREER2.1620e-040.2145image
chr2:218231826-218234095:+STADGSVA_HALLMARK_PROTEIN_SECRETIONEER2.4738e-020.2683image
ENSG00000163466.14,ARPC2STADGSVA_HALLMARK_DNA_REPAIREAG3.3435e-050.2363image
ENSG00000163466.14,ARPC2TGCTGSVA_HALLMARK_SPERMATOGENESISEAG4.2729e-020.2447image
chr2:218235187-218237907:+TGCTGSVA_HALLMARK_SPERMATOGENESISEER4.2729e-020.2447image
ENSG00000163466.14,ARPC2UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.2231e-020.5487image


Top

7. Enriched editing regions and drugs for ARPC2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr2:218235187-218237907:+BLCAJW.7.52.1EER1.7536e-03-0.2279image
ENSG00000163466.14,ARPC2BLCAJW.7.52.1EAG8.8711e-04-0.2417image
ENSG00000163466.14,ARPC2BRCABosutinibEAG8.6314e-030.1375image
chr2:218235187-218237907:+BRCABosutinibEER8.9547e-030.1372image
chr2:218235187-218237907:+COADBicalutamideEER8.0323e-03-0.2316image
ENSG00000163466.14,ARPC2COADBicalutamideEAG1.1707e-02-0.2205image
chr2:218235187-218237907:+DLBCAZD.2281EER7.3082e-030.5674image
ENSG00000163466.14,ARPC2DLBCAZD.2281EAG7.3092e-030.5674image
chr2:218235187-218237907:+ESCABMS.536924EER1.1406e-03-0.2589image
ENSG00000163466.14,ARPC2ESCABMS.536924EAG1.1054e-03-0.2588image
chr2:218251240-218252221:+ESCAATRAEER3.8889e-020.4536image
chr2:218231826-218234095:+ESCABryostatin.1EER3.0540e-030.4274image
chr2:218235187-218237907:+GBMCisplatinEER2.5847e-040.4778image
ENSG00000163466.14,ARPC2GBMCisplatinEAG2.6991e-040.4765image
chr2:218235187-218237907:+HNSCAG.014699EER1.3410e-020.2206image
ENSG00000163466.14,ARPC2HNSCAG.014699EAG1.3348e-020.2208image
chr2:218235187-218237907:+KIRCATRAEER3.1319e-040.2764image
ENSG00000163466.14,ARPC2KIRCATRAEAG2.7684e-040.2787image
ENSG00000163466.14,ARPC2KIRPAS601245EAG1.9231e-030.3244image
chr2:218235187-218237907:+KIRPAS601245EER2.0552e-030.3225image
chr2:218235187-218237907:+LAMLA.770041EER6.4464e-04-0.2755image
ENSG00000163466.14,ARPC2LAMLA.770041EAG5.9033e-04-0.2774image
chr2:218235187-218237907:+LUADLFM.A13EER9.9898e-050.2296image
ENSG00000163466.14,ARPC2LUADLFM.A13EAG8.8074e-050.2310image
chr2:218235187-218237907:+LUSCAZD6482EER2.6328e-040.1933image
ENSG00000163466.14,ARPC2LUSCAZD6482EAG2.9801e-040.1914image
chr2:218235187-218237907:+MESOAMG.706EER2.6719e-020.3915image
ENSG00000163466.14,ARPC2MESOAMG.706EAG2.6719e-020.3915image
ENSG00000163466.14,ARPC2OVDMOGEAG5.7291e-030.2029image
chr2:218235187-218237907:+OVDMOGEER1.3268e-030.2349image
chr2:218235187-218237907:+PAADBleomycinEER6.5885e-030.2576image
ENSG00000163466.14,ARPC2PAADBleomycinEAG6.5828e-030.2576image
chr2:218235187-218237907:+PRADJNK.9LEER8.3074e-040.6253image
ENSG00000163466.14,ARPC2PRADJNK.9LEAG1.4193e-030.5927image
ENSG00000163466.14,ARPC2READCCT007093EAG4.0240e-020.3217image
chr2:218235187-218237907:+READCCT007093EER4.0240e-020.3217image
chr2:218235187-218237907:+SARCBMS.754807EER8.4146e-030.4062image
ENSG00000163466.14,ARPC2SARCBMS.754807EAG8.4146e-030.4062image
ENSG00000163466.14,ARPC2SKCMBAY.61.3606EAG3.8026e-050.3443image
chr2:218235187-218237907:+SKCMBAY.61.3606EER3.8026e-050.3443image
chr2:218251240-218252221:+STADAZD.2281EER5.0919e-03-0.6008image
chr2:218235187-218237907:+STADBAY.61.3606EER1.3851e-040.2208image
chr2:218231826-218234095:+STADBMS.708163EER1.2059e-02-0.2986image
ENSG00000163466.14,ARPC2STADBAY.61.3606EAG4.9609e-050.2313image
ENSG00000163466.14,ARPC2TGCTGW.441756EAG1.3002e-02-0.2976image
chr2:218235187-218237907:+TGCTGW.441756EER1.3002e-02-0.2976image
ENSG00000163466.14,ARPC2THCAGefitinibEAG2.0443e-02-0.2526image
chr2:218235187-218237907:+THCAGefitinibEER2.0443e-02-0.2526image
chr2:218235187-218237907:+THYMJNK.Inhibitor.VIIIEER1.3785e-020.3607image
ENSG00000163466.14,ARPC2THYMJNK.Inhibitor.VIIIEAG1.3785e-020.3607image
ENSG00000163466.14,ARPC2UCECGDC.0449EAG2.8065e-03-0.6318image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType